Tralokinumab appears effective in severe atopic dermatitis in real-world setting

Tralokinumab shows promising short-term effectiveness and safety in treating moderate to severe atopic dermatitis (AD) patients, according to a recent retrospective study conducted in 16 Spanish hospitals.

Tralokinumab is the first selective IL-13 inhibitor that specifically neutralizes IL-13 with high affinity and was recently approved for the treatment of moderate to severe AD. To determine the real-life short-term effectiveness and safety of Tralokinumab treatment, a retrospective study was conducted including adult patients with moderate to severe AD who initiated Tralokinumab treatment.

The study included 85 patients, of which 27 (31.8%) were non-naïve to advanced therapy (biological or JAK inhibitors). All included patients had severe disease with baseline Eczema Area and Severity Index (EASI) scores of 25.4 ± 8.1, Dermatology Life Quality Index (DLQI) 15.8 ± 5.4, and Peak Pruritus Numerical Rating Scale (PP-NRS) 8.1 ± 1.8. At week 16, all scales improved significantly. The mean EASI decreased to 7.5 ± 6.9 (70.4% improvement), SCORAD improved 64.1%, and PP-NRS, 57.1%. Furthermore, 82.4%, 57.6%, and 21.2% of the patients achieved EASI 50, 75 and 90, respectively.

Patients with a long history of disease and prior multidrug failure showed a good response to Tralokinumab, confirming clinical trial results. However, the percentage of EASI75 responders was significantly higher among naïve versus non-naïve patients (67.2% vs 40.7%).

This study provides evidence that Tralokinumab is an effective and safe treatment option for patients with moderate to severe AD, even those who have failed prior advanced therapies.

Reference
Pereyra-Rodriguez JJ, Herranz P, Ruiz-Villaverde R, et al. Treatment of severe atopic dermatitis with Tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. 2023 Apr 25:llad153. doi: 10.1093/ced/llad153. Epub ahead of print. PMID: 37098171.